digital pill

By Dave Muoio 03:23 pm August 20, 2020
Picking through the scraps. Following the bankruptcy of 'digital pill' maker Proteus Digital Health, business partner and stakeholder Otsuka Pharmaceutical has been approved to purchase the digital health company's assets by a federal bankruptcy court judge, STAT reports. Otsuka's bid was challenged by Novartis, two former Proteus executives and other investors, who argued that the agreed upon $...
By Dave Muoio 02:51 pm June 16, 2020
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday. The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment. The "smart pill" maker...
By Dave Muoio 02:45 pm January 14, 2020
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments. The pharmaceutical company has now acquired the full license for Proteus’ mental health...
By Dave Muoio 04:03 pm December 9, 2019
Gainesville, Florida-based etectRx has received FDA 510(k) clearance for its ID-Cap System, a prescription ingestible system that sends adherence event logs to an external medical device. Similar to the system pioneered by etectRx’s high-profile competitor, Proteus Digital Health, the ID-Cap’s core is a standard capsule containing a sensor that transmits a message once it comes into contact with...
By Dave Muoio 01:03 pm December 9, 2019
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC. These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
By Dave Muoio 03:18 pm October 7, 2019
Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California. Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home...
By Dave Muoio 12:34 pm January 17, 2019
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic. According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...
By Dave Muoio 04:23 pm October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics. On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
By Laura Lovett 03:58 pm October 10, 2018
Children’s Health, a Texas-based pediatric health system, is teaming up with Proteus to pilot a new program aimed at tackling adherence issues in pediatric heart transplant patients by inserting ingestible sensors into prescribed pills, which can track when the medication was taken.  The system is made up of a wearable patch worn by the patient and the sensor-infused pill. When the pill is broken...
By Dave Muoio 04:01 pm August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale. “We are eager for...